Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.46 |
| ▸ | HTR1B | P28222 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | THRA | P10827 | 5/20 | 0.40 |
| ▸ | THRB | P10828 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15912345 | 0.89 | HTR1D (0.57) | HTR1DHTR1BHTR2AHTR2CHTR2B | |
| SCHEMBL4503796 | 0.80 | HTR2A (0.55) | HTR2AHTR2CGPR84 | |
| SCHEMBL14555321 | 0.80 | ATM (0.47) | HTR1DHTR1BHTR2AHTR2CHTR2B | |
| SCHEMBL12244348 | 0.78 | TP53 (0.50) | HTR1DHTR2AHTR2CHTR2BFFAR1 | |
| SCHEMBL22643949 | 0.77 | HTR1D (0.49) | HTR1DHTR1BHTR2AHTR2CHTR2B | |
| SCHEMBL23612239 | 0.76 | HTR1D (0.44) | HTR1DHTR1BHTR2AHTR2CHTR2B | |
| SCHEMBL15724409 | 0.76 | HTR2A (0.45) | HTR1DHTR1BHTR2AHTR2CHTR2B | |
| SCHEMBL12244358 | 0.76 | HTR2A (0.55) | HTR2AGPR84GUSB | |
| SCHEMBL3156224 | 0.76 | SRC (0.54) | HTR2AHTR2CHTR2BGPR84GUSB | |
| SCHEMBL6516528 | 0.76 | HTR2C (0.55) | HTR1DHTR1BHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | HTR1D 4753/4885HTR1B 4456/4885HTR2A 4866/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR1D 4753/4885HTR1B 4456/4885HTR2A 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.